EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients

Yasumasa Shimasaki, Hiroaki Miyoshi iD, Keisuke Kawamoto, Noriaki Yoshida, Tatsuzo Mishina, Kazutaka Nakashima, Teppei Imamoto, Takeshi Sugio, Eriko Yanagida, Takeharu Kato, Kyohei Yamada, Mai Takeuchi und 9 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yasumasa Shimasaki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Kurume University, Kurume, Japan. Hauptthemen laut MEDLINE: Algorithms, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Peripheral T‐cell lymphoma not otherwise specified (PTCL‐NOS) is a heterogeneous disease that can be classified into the PTCL‐TBX21 and PTCL‐GATA3 subtypes.

Methods

In this study, we compared the clinicopathological features of PTCL‐NOS in a Japanese cohort, classified using an IHC algorithm.

Results

One hundred patients with PTCL‐NOS were categorized as having PTCL‐TBX21 ( n = 55), PTCL‐GATA3 ( n = 24), or PTCL‐unclassified ( n = 21). When comparing PTCL‐TBX21 and PTCL‐GATA3, PTCL‐TBX21 showed significantly lower CD4 positivity ( p = 0.047), lower counts of high endothelial venules ( p = 0.032), and a tendency for a better response to initial treatment ( p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity‐related genes, such as PD‐L1, LAG3, and IDO1, in PTCL‐TBX21 than in PTCL‐GATA3. PTCL‐GATA3 had significantly worse overall survival (OS) than those with PTCL‐TBX21 ( p = 0.047), although a similar tendency was observed for progression‐free survival (PFS) ( p = 0.064). PTCL‐GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09–3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93–4.61; p = 0.074). In the PFS analysis, PTCL‐GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08–3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07–5.11; p = 0.032).

Conclusion

The classification of PTCL‐NOS into PTCL‐TBX21 and PTCL‐GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlgorithmsLymphoma, T-Cell, PeripheralHumansJapanGene Expression ProfilingImmune Checkpoint InhibitorsGATA3 Transcription Factor

Stichwörter der Autor:innen

PTCL-GATA3PTCL-TBX21pathologyperipheral T-cell lymphoma not otherwise specified

Substanzen

Immune Checkpoint InhibitorsGATA3 protein, humanGATA3 Transcription Factor

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, Kurume University, Kurume, Japan.
  • Department of Hematology, Shimane University Hospital, Izumo, Japan.
  • Department of Hematology, Endocrinology, and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
  • Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima, Japan.
  • Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.

ORCID-Profile: Hiroaki Miyoshi, Mayuko Moritsubo, Yoshitaka Imaizumi

Zitieren

APA

Shimasaki, Y., Miyoshi, H., Kawamoto, K., Yoshida, N., Mishina, T., Nakashima, K., Imamoto, T., Sugio, T., Yanagida, E., Kato, T., Yamada, K., Takeuchi, M., Suzuki, T., Moritsubo, M., Furuta, T., Imaizumi, Y., Takizawa, J., Kato, K., Suzumiya, J., …, & Ohshima, K. (2024). Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients. Cancer Medicine. https://doi.org/10.1002/cam4.6793

Vancouver

Shimasaki Y, Miyoshi H, Kawamoto K, Yoshida N, Mishina T, Nakashima K, et al. Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients. Cancer Medicine. 2024. doi:10.1002/cam4.6793

BibTeX
@article{Shimasaki2024,
  author = {Shimasaki, Yasumasa and Miyoshi, Hiroaki and Kawamoto, Keisuke and Yoshida, Noriaki and Mishina, Tatsuzo and Nakashima, Kazutaka and Imamoto, Teppei and Sugio, Takeshi and Yanagida, Eriko and Kato, Takeharu and Yamada, Kyohei and Takeuchi, Mai and Suzuki, Takaharu and Moritsubo, Mayuko and Furuta, Takuya and Imaizumi, Yoshitaka and Takizawa, Jun and Kato, Koji and Suzumiya, Junji and Suzuki, Ritsuro and Ohshima, Koichi},
  title = {Clinicopathological comparison between PTCL‐TBX21 and PTCL‐GATA3 in Japanese patients},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6793}
}
Kostenlos starten →